Clinical Trials Sponsored by Modra Pharmaceuticals

Total 19818 results

Boston Pharmaceuticals

Completed

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Healthy Participants

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Psoriasis

Australia
Boston Pharmaceuticals

Completed

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Healthy Subjects

United Kingdom
Boston Pharmaceuticals

Completed

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects

Healthy Participants

United Kingdom
Ferring Pharmaceuticals

Completed

A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

Infertility

Belgium, Denmark, Spain, Czechia
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
Endo Pharmaceuticals

Completed

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women (RELEASE-2)

Edematous Fibrosclerotic Panniculopathy (Cellulite)

United States
Aerie Pharmaceuticals

Completed

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Ocular Hypertension | Glaucoma, Open-Angle

United States
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
Processa Pharmaceuticals

Terminated

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
Jazz Pharmaceuticals

Approved for marketing

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Small Cell Lung Cancer
Ferring Pharmaceuticals

Completed

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Alnylam Pharmaceuticals

Terminated

A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Amyloidosis | Leukocyte Chemotactic Factor 2 Amyloidosis

United States, Malaysia, United Kingdom, Mexico, Egypt, India
Hope Pharmaceuticals

Terminated

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients (CALISTA)

Calciphylaxis

United States, Canada, United Kingdom
Quark Pharmaceuticals

Completed

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

Delayed Graft Function

United States, Spain, Canada, Australia, Netherlands, Germany, Belgium, France, Argentina, Brazil, Czechia
Braeburn Pharmaceuticals

Completed

Phase II Pharmacokinetics Study of CAM2038

Chronic Pain | Opioid Use Disorder

United States
Vanda Pharmaceuticals

Unknown

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Coronavirus Infection

United States
Veloxis Pharmaceuticals

Terminated

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Autoimmune Hepatitis

United States, Canada
Veloxis Pharmaceuticals

Completed

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

Dyslipidemia

United States
Alexion Pharmaceuticals

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (EVIDENCE)

Atypical Hemolytic Uremic Syndrome

United States, Australia, Germany, United Kingdom
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Syndax Pharmaceuticals

Terminated

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (ENGAGE-501)

Hodgkin's Lymphoma

United States
Ferring Pharmaceuticals

Completed

Cortiment® MMX Pharmacokinetic Study

Healthy

India
Bellicum Pharmaceuticals

Completed

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Castrate Resistent Prostate Cancer

United States
Alexion Pharmaceuticals

Terminated

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Canada, United Kingdom
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Endo Pharmaceuticals

Completed

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

Edematous Fibrosclerotic Panniculopathy

United States
Ferring Pharmaceuticals

Terminated

A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Portal Hypertension

Spain
Ferring Pharmaceuticals

Completed

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Advanced Prostate Cancer

Germany
Alexion Pharmaceuticals

Terminated

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, United States, United Kingdom, Croatia, Malaysia, Korea, Republic of, Turkey, Japan, Italy, Spain, Taiwan, Australia, Argentina, Thailand, Russian Federation, Czechia, Denmark, Germany
Ferring Pharmaceuticals

Completed

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Prostate Cancer

United Kingdom, Netherlands, Ireland, Greece, France, Belgium, Denmark, Norway, Italy, Slovakia, Switzerland, Portugal, Finland, Hungary, Germany
Jazz Pharmaceuticals

Completed

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

Obstructive Sleep Apnea | Narcolepsy

United States, France, Canada, Germany, Netherlands, Finland
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Alexion Pharmaceuticals

Completed

Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Stage V Chronic Kidney Disease

Australia, France, Italy, Spain, United Kingdom, Sweden
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Arrowhead Pharmaceuticals

Terminated

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Hepatitis B

Korea, Republic of, Germany, China
Arrowhead Pharmaceuticals

Terminated

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B

Korea, Republic of, Germany, China
Alexion Pharmaceuticals

Completed

Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada
Alexion Pharmaceuticals

Approved for marketing

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia

United States, France
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
Impel Pharmaceuticals

Completed

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Migraine Headache

Australia
Alexion Pharmaceuticals

Completed

Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09

Hypophosphatasia | Bone Disease

United States
Alexion Pharmaceuticals

Completed

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Spain, Australia, United Kingdom, Italy, France, Canada, Germany, Japan, Russian Federation, Saudi Arabia, Turkey
Alexion Pharmaceuticals

Terminated

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Multiple Myeloma | B-cell Chronic Lymphocytic Leukemia

United States

3

Subscribe